Risk for late-occurring thromboembolism was elevated in patients who underwent allogeneic transplantation, and risk factors varied by transplantation type.
Long-term oral anticoagulation with vitamin K antagonists is recommended for most patients with myeloproliferative neoplasms experiencing thrombosis.
A new risk stratification score for venous thromboembolism was developed and validated in a cohort of more than 4000 patients with multiple myeloma.
Rituximab treatment conferred short-term benefit against subsequent relapse, though this benefit decreased over time.
Similar rates of thrombotic events occurred in patients with FXII deficiency and unaffected controls.
Researchers conducted the first real world study to compare the safety and effectiveness of apixaban and rivaroxaban in patients with VTE.
